Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 441

1.

Gene therapy improves brain white matter in aromatic l-amino acid decarboxylase deficiency.

Tseng CH, Chien YH, Lee NC, Hsu YC, Peng SF, Tseng WI, Hwu WL.

Ann Neurol. 2019 Mar 12. doi: 10.1002/ana.25467. [Epub ahead of print]

PMID:
30864153
2.

Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses.

Lin HY, Chan WC, Chen LJ, Lee YC, Yeh SI, Niu DM, Chiu PC, Tsai WH, Hwu WL, Chuang CK, Lin SP.

Mol Genet Genomic Med. 2019 Mar 8:e00617. doi: 10.1002/mgg3.617. [Epub ahead of print]

3.

Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency.

Ho SY, Chien YH, Tsai LK, Muramatsu SI, Hwu WL, Liou HH, Lee NC.

Front Cell Neurosci. 2019 Jan 31;13:9. doi: 10.3389/fncel.2019.00009. eCollection 2019.

4.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Jan 31. doi: 10.1093/annonc/mdz011. [Epub ahead of print]

PMID:
30715153
5.

Reply to Lutz-Bonengel et al.: Biparental mtDNA transmission is unlikely to be the result of nuclear mitochondrial DNA segments.

Luo S, Valencia CA, Zhang J, Lee NC, Slone J, Gui B, Wang X, Li Z, Dell S, Brown J, Chen SM, Chien YH, Hwu WL, Fan PC, Wong LJ, Atwal PS, Huang T.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):1823-1824. doi: 10.1073/pnas.1821357116. Epub 2019 Jan 23. No abstract available.

PMID:
30674682
6.

Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia.

Juang JJ, Shun CT, Chen YS, Hwu WL, Lee NC, Tsai WH, Chen NQ, Chien YH.

Genet Med. 2019 Jan 21. doi: 10.1038/s41436-019-0436-y. [Epub ahead of print] No abstract available.

PMID:
30662066
7.

Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population.

Hsu RH, Chien YH, Hwu WL, Chang IF, Ho HC, Chou SP, Huang TM, Lee NC.

Orphanet J Rare Dis. 2019 Jan 7;14(1):6. doi: 10.1186/s13023-018-0992-2.

8.

A review of aromatic l-amino acid decarboxylase (AADC) deficiency in Taiwan.

Lee NC, Chien YH, Hwu WL.

Am J Med Genet C Semin Med Genet. 2019 Jan 7. doi: 10.1002/ajmg.c.31670. [Epub ahead of print]

PMID:
30614627
9.

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.

McQuade JL, Homsi J, Torres-Cabala CA, Bassett R, Popuri RM, James ML, Vence LM, Hwu WJ.

BMC Cancer. 2018 Dec 19;18(1):1274. doi: 10.1186/s12885-018-5193-9.

10.

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).

Wasserstein M, Dionisi-Vici C, Giugliani R, Hwu WL, Lidove O, Lukacs Z, Mengel E, Mistry PK, Schuchman EH, McGovern M.

Mol Genet Metab. 2019 Feb;126(2):98-105. doi: 10.1016/j.ymgme.2018.11.014. Epub 2018 Nov 29. Review.

11.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340. No abstract available.

PMID:
30510087
12.

Biparental Inheritance of Mitochondrial DNA in Humans.

Luo S, Valencia CA, Zhang J, Lee NC, Slone J, Gui B, Wang X, Li Z, Dell S, Brown J, Chen SM, Chien YH, Hwu WL, Fan PC, Wong LJ, Atwal PS, Huang T.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13039-13044. doi: 10.1073/pnas.1810946115. Epub 2018 Nov 26.

PMID:
30478036
13.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
14.

Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.

Lin CJ, Chien YH, Lai TS, Shih HM, Chen YC, Pan CF, Chen HH, Hwu WL, Wu CJ.

Kidney Blood Press Res. 2018;43(5):1636-1645. doi: 10.1159/000494678. Epub 2018 Oct 31.

15.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
16.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
17.

Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.

Sagiv O, Thakar SD, Kandl TJ, Ford J, Sniegowski MC, Hwu WJ, Esmaeli B.

JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241. doi: 10.1001/jamaophthalmol.2018.3488.

PMID:
30352118
18.

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

Kim K, Chung TH, Etzel CJ, Kim J, Ryu H, Kim DW, Hwu P, Hwu WJ, Patel SP, Liu M, Kim KB.

Cancer Epidemiol. 2018 Dec;57:80-84. doi: 10.1016/j.canep.2018.10.003. Epub 2018 Oct 19.

PMID:
30347335
19.

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A.

J Immunother Cancer. 2018 Oct 11;6(1):103. doi: 10.1186/s40425-018-0412-0.

20.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

PMID:
30297909
21.

Mycobacterium abscessus infection in a boy with X-linked anhidrotic ectodermal dysplasia, immunodeficiency.

Yu HH, Hu TC, Lee NC, Chien YH, Yang YH, Hwu WL, Chiang BL.

J Microbiol Immunol Infect. 2018 Aug 31. pii: S1684-1182(18)30337-2. doi: 10.1016/j.jmii.2018.04.009. [Epub ahead of print] No abstract available.

22.

Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA.

Lin HY, Chuang CK, Ke YY, Hsu CC, Chiu PC, Niu DM, Tsai FJ, Hwu WL, Lin JL, Lin SP.

Pediatr Neonatol. 2018 Aug 23. pii: S1875-9572(18)30270-5. doi: 10.1016/j.pedneo.2018.08.005. [Epub ahead of print] No abstract available.

23.

Disease progression in a pre-symptomatically treated patient with juvenile-onset Pompe disease - need for an earlier treatment?

Chien YH, Lee NC, Hwu WL, Fang JY.

Eur J Neurol. 2018 Oct;25(10):e111. doi: 10.1111/ene.13730. No abstract available.

PMID:
30192061
24.

Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial.

Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu SI, Byrne BJ, Hwu WL.

Lancet Child Adolesc Health. 2017 Dec;1(4):265-273. doi: 10.1016/S2352-4642(17)30125-6. Epub 2017 Oct 23.

PMID:
30169182
25.

Mucopolysaccharidosis III in Taiwan: Natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21-year period.

Lin HY, Chuang CK, Lee CL, Tu RY, Lo YT, Chiu PC, Niu DM, Fang YY, Chen TL, Tsai FJ, Hwu WL, Lin SJ, Chang TM, Lin SP.

Am J Med Genet A. 2018 Sep;176(9):1799-1809. doi: 10.1002/ajmg.a.40351. Epub 2018 Aug 2.

PMID:
30070758
26.

Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS).

Lin HY, Chuang CK, Chen MR, Lin SJ, Chiu PC, Niu DM, Tsai FJ, Hwu WL, Chien YH, Lin JL, Lin SP.

Orphanet J Rare Dis. 2018 Jun 4;13(1):89. doi: 10.1186/s13023-018-0827-1.

27.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
28.

Next-generation sequencing identifies TRPV4-related skeletal dysplasia in a boy with progressive bowlegs.

Hsu RH, Hwu WL, Chen M, Chung IF, Peng SS, Chen CY, Cheng WC, Chien YH, Lee NC.

Pediatr Neonatol. 2019 Feb;60(1):102-104. doi: 10.1016/j.pedneo.2018.04.002. Epub 2018 Apr 13. No abstract available.

29.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6098.

PMID:
29685882
30.

Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.

Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):504-507. doi: 10.1111/cup.13150. Epub 2018 Apr 23.

PMID:
29633300
31.

Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.

Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP.

Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000436. [Epub ahead of print]

PMID:
29509591
32.

Congenital generalized lipodystrophy in Taiwan.

Hsu RH, Lin WD, Chao MC, Hsiao HP, Wong SL, Chiu PC, Chu SY, Ke YY, Lau BH, Chien YH, Hwu WL, Tsai FJ, Wang CH, Lee NC.

J Formos Med Assoc. 2019 Jan;118(1 Pt 1):142-147. doi: 10.1016/j.jfma.2018.02.003. Epub 2018 Mar 1.

33.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22.

34.
35.

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA.

ESMO Open. 2018 Jan 24;3(1):e000283. doi: 10.1136/esmoopen-2017-000283. eCollection 2018.

36.

Comprehensive human leukocyte antigen genotyping of patients with type 1 diabetes mellitus in Taiwan.

Tung YC, Fann CS, Chang CC, Chu CC, Yang WS, Hwu WL, Chen PL, Tsai WY.

Pediatr Diabetes. 2018 Jun;19(4):699-706. doi: 10.1111/pedi.12645. Epub 2018 Jan 31.

PMID:
29383806
37.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
38.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A.

Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22.

PMID:
29358500
39.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

40.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.

PMID:
29283791
41.

SHOX deficiency in short Taiwanese children: A single-center experience.

Tung YC, Lee NC, Hwu WL, Liu SY, Lee CT, Chien YH, Tsai WY.

J Formos Med Assoc. 2018 Oct;117(10):909-914. doi: 10.1016/j.jfma.2017.11.014. Epub 2017 Dec 16.

42.

Desmoplastic Melanoma of the Periorbital Region.

Thakar S, Kandl T, Sagiv O, Tripathy D, Tetzlaff MT, Kapur S, Myers J, Hwu WJ, Jaber BMY, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):e48-e52. doi: 10.1097/IOP.0000000000001015.

PMID:
29194286
43.

Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors.

Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS.

J Comput Assist Tomogr. 2018 May/Jun;42(3):357-364. doi: 10.1097/RCT.0000000000000686.

PMID:
29189398
44.

Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.

Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, Swoboda KJ, Kishnani PS; Pompe Disease Newborn Screening Working Group.

Pediatrics. 2017 Jul;140(Suppl 1):S24-S45. doi: 10.1542/peds.2016-0280E.

45.

The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease.

Burton BK, Kronn DF, Hwu WL, Kishnani PS; Pompe Disease Newborn Screening Working Group.

Pediatrics. 2017 Jul;140(Suppl 1):S14-S23. doi: 10.1542/peds.2016-0280D.

46.

Introduction to the Newborn Screening, Diagnosis, and Treatment for Pompe Disease Guidance Supplement.

Kishnani PS, Hwu WL; Pompe Disease Newborn Screening Working Group.

Pediatrics. 2017 Jul;140(Suppl 1):S1-S3. doi: 10.1542/peds.2016-0280B. Review. No abstract available.

47.

Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10.

Cheng W, Huang PC, Chao HM, Jeng YM, Hsu HC, Pan HW, Hwu WL, Lee YM.

Oncotarget. 2017 Jul 6;8(46):80429-80442. doi: 10.18632/oncotarget.19035. eCollection 2017 Oct 6.

48.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

49.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

50.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

Supplemental Content

Support Center